Gsa Capital Partners LLP Bio N Tech Se Transaction History

Gsa Capital Partners LLP

10 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Nov 05, 2024	BUY	$78.36 - $124.66 $245,893 - $391,183	3,138 New	3,138 $373,000
Q1 2024 May 03, 2024	BUY	$88.96 - $112.35 $322,480 - $407,268	3,625 New	3,625 $334,000
Q2 2023 Aug 14, 2023	BUY	$102.58 - $129.66 $45,237 - $57,180	441 Added 8.7%	5,510 $594,000
Q1 2023 May 12, 2023	BUY	$122.57 - $153.67 $80,283 - $100,653	655 Added 14.84%	5,069 $631,000
Q4 2022 Feb 13, 2023	BUY	$118.43 - $186.05 $522,750 - $821,224	4,414 New	4,414 $663,000
Q2 2022 Aug 09, 2022	BUY	$123.25 - $186.24 $461,324 - $697,096	3,743 New	3,743 $558,000
Q1 2022 May 11, 2022	SELL	$126.25 - $231.85 $154,908 - $284,479	-1,227 Closed	0 $0
Q4 2021 Feb 14, 2022	BUY	$216.64 - $362.52 $265,817 - $444,812	1,227 New	1,227 $316,000
Q3 2021 Nov 12, 2021	SELL	$205.93 - $447.23 $339,166 - $736,587	-1,647 Closed	0 $0
Q2 2021 Aug 05, 2021	BUY	$113.32 - $241.49 $186,638 - $397,734	1,647 New	1,647 $369,000

363

38.3M

2.45M

2.29M

Ticker BNTX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 242,684,992
Market Cap $28.5B
Description
BioNTech SE, a biotechnology company, develops and commercializes immunotherapies for cancer and other infectious diseases. The company is developing FixVac product candidates, including BNT111, which is in Phase II clinical trial for advance melanoma; BNT112 that is in Phase I/IIa clinical trial for prostate cancer; BNT113, which is in Phase II...

Get notified when there are updates to the investment portfolio of Gsa Capital Partners LLP, based on Form 13F filings with the SEC.

Stay updated on Gsa Capital Partners LLP with notifications on news.